Resting State Changes Following Theta Burst Stimulation
Launched by NICHOLAS BALDERSTON, PHD · Apr 8, 2022
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a treatment called transcranial magnetic stimulation (TMS) affects the way different areas of the brain connect with each other. TMS is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain, and it's increasingly being used to help treat mental health conditions. The researchers aim to understand better how TMS changes brain connectivity, which could help predict improvements in psychiatric symptoms for those undergoing this treatment.
To participate in the trial, individuals should be right-handed and able to give their consent. However, there are some important exclusions: people with significant medical issues, a history of severe mental health disorders, or those who have had seizures or certain neurological problems cannot take part. The trial is currently looking for participants aged between 65 and 74 and also welcomes all genders. If eligible, participants can expect to undergo brain scans and TMS sessions while contributing to important research that could enhance future mental health treatments.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Able to give their consent
- • Right-handed
- • Exclusion Criteria
- • Non-english speaking
- • Any significant medical problems
- • Current or past Axis I psychiatric disorder(s),
- • Active or history of active suicidal ideation
- • Alcohol/drug problems in the past year or lifetime alcohol or drug dependence
- • Medications that act on the central nervous system
- • History of seizure
- • History of epilepsy or other neurological problems
- • Increased risk of seizure for any reason
- • Pregnancy
- • Any medical condition that increases risk for fMRI or TMS
- • Any metal in their body which would make having an MRI scan unsafe
- • Any sort of medical implants
- • Claustrophobia
About Nicholas Balderston, Phd
Nicholas Balderston, PhD, is a distinguished clinical trial sponsor with a robust background in biomedical research and drug development. With a focus on advancing innovative therapeutic solutions, Dr. Balderston leads initiatives that explore novel treatment modalities across various therapeutic areas. His expertise in clinical trial design, regulatory compliance, and data analysis ensures the successful execution of studies aimed at improving patient outcomes. Committed to fostering collaboration and transparency, Dr. Balderston is dedicated to driving scientific advancements that address unmet medical needs and enhance the overall quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Nicholas L Balderston
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials